Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Tuesday, January 25th, 2022

This study evaluated the validity of the cough severity visual analog scale in 253 patients with refractory or unexplained chronic cough who participated in a Phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant. As part of the study, objective cough frequency was monitored using the Vitalograph VitaloJAK ambulatory cough recorder.